No More Mr. NICE Guy: Pfizer/Eisai Seek Court Review Of Cost-Effectiveness Appraisal For Alzheimer’s Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Judicial review of U.K. appraisal limiting acetylcholinesterase inhibitors to moderately severe Alzheimer’s would mark the first time NICE has been challenged at that level, firms say.
You may also be interested in...
Eisai Formally Requests Judicial Review Of NICE Alzheimer’s Appraisal
Grounds for review include procedural issues, irrationality and human rights, according to Eisai.
Eisai Formally Requests Judicial Review Of NICE Alzheimer’s Appraisal
Grounds for review include procedural issues, irrationality and human rights, according to Eisai.
NICE To Release Final Alzheimer's Guidance Nov. 22
Appeals by industry and the Alzheimer's Society were not granted, the U.K. agency says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: